NorthSea Therapeutics

Scroll
Investment area
Novo Seeds
Region
Europe
Date of investment
December 2017
Website
https://www.northseatherapeutics.com/

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.